Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group
Helena Linardou(Metropolitan Hospital), George Fountzilas(Aristotle University of Thessaloniki), George Saroglou(National and Kapodistrian University of Athens), Zacharenia Saridaki(Clinic Asklepio Larissa), Nephely Alevra(Metropolitan Hospital), Nikolaos Tsoukalas(401 General Military Hospital of Athens), Sofia Karageorgopoulou(National and Kapodistrian University of Athens), Eleni Res(Hospital Agioi Anargyroi), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Sofia Lampaki(Aristotle University of Thessaloniki), Giannis Mountzios(Henry Dunant Hospital), Nikolaos Spanakis(National and Kapodistrian University of Athens), Athina Christopoulou(Agios Andreas Hospital), Anastasios Vagionas(Technological Educational Institute of Eastern Macedonia and Thrace), Dimitra Chatzokou, Stavroula Sgourou(Metropolitan Hospital), Elena Fountzilas(European University Cyprus), Evangelia Razis(Hygeia Hospital), Joseph Sgouros(Hospital Agioi Anargyroi)
Cited by 41
Related Papers
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488
Clinical trial design in the era of precision medicine
|Genome Medicine|2022|279
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
|Cancer Research|2011|266
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181